These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8100642)

  • 21. [Clozapine and treatment of negative symptoms].
    Lançon C; Farisse J; Llorca PM
    Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
    Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M
    Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychopharmacologic treatment of negative schizophrenic symptoms.
    Opler LA; Albert D; Ramirez PM
    Compr Psychiatry; 1994; 35(1):16-28. PubMed ID: 7908618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
    Goldberg TE; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
    Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
    Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional antipsychotic medications for schizophrenia.
    Dixon LB; Lehman AF; Levine J
    Schizophr Bull; 1995; 21(4):567-77. PubMed ID: 8749885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
    Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
    Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel neuroleptics in schizophrenia: theory and clinical relevance.
    Remington GJ
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S43-5. PubMed ID: 7533050
    [No Abstract]   [Full Text] [Related]  

  • 37. Information processing and maintenance dose requirements in schizophrenia.
    Marder SR; Asarnow RF; Van Putten T
    Psychopharmacol Bull; 1988; 24(2):247-50. PubMed ID: 2905506
    [No Abstract]   [Full Text] [Related]  

  • 38. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
    Kasper S; Lerman MN; McQuade RD; Saha A; Carson WH; Ali M; Archibald D; Ingenito G; Marcus R; Pigott T
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):325-37. PubMed ID: 14609439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.